Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Krystal Biotech (KRYS) EPS (Basic) (2021 - 2026)

Krystal Biotech's EPS (Basic) history spans 6 years, with the latest figure at $1.91 for Q1 2026.

  • On a quarterly basis, EPS (Basic) rose 54.03% to $1.91 in Q1 2026 year-over-year; TTM through Mar 2026 was $7.75, a 79.4% increase, with the full-year FY2025 number at $7.08, up 126.92% from a year prior.
  • EPS (Basic) hit $1.91 in Q1 2026 for Krystal Biotech, up from $1.77 in the prior quarter.
  • Over the last five years, EPS (Basic) for KRYS hit a ceiling of $2.88 in Q3 2023 and a floor of -$1.99 in Q1 2022.
  • Historically, EPS (Basic) has averaged $0.4 across 5 years, with a median of $0.54 in 2024.
  • Biggest five-year swings in EPS (Basic): tumbled 168.92% in 2022 and later soared 4033.33% in 2025.
  • Tracing KRYS's EPS (Basic) over 5 years: stood at -$1.25 in 2022, then surged by 125.6% to $0.32 in 2023, then soared by 396.88% to $1.59 in 2024, then rose by 11.32% to $1.77 in 2025, then rose by 7.91% to $1.91 in 2026.
  • Business Quant data shows EPS (Basic) for KRYS at $1.91 in Q1 2026, $1.77 in Q4 2025, and $2.74 in Q3 2025.